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ABSTRACT 
Malaria is one of the most threatening parasitic diseases, being endemic in most of the 
tropical and subtropical countries. This problem becomes severe with the rapid spread of 
drug resistant Plasmodium falciparum, development of resistance to insecticides by 
Anopheles mosquito, poor hygienic care, socioeconomic problems and transition of 
people. Therefore an effective and universal malaria vaccine against Plasmodium 
falciparum should be developed. A great deal effort of researchers nowadays has been 
focused on vaccines targeting at the asexual blood stage due to prolong life cycle within 
the blood and it can directly reduce morbidity and mortality associated with malarial 
disease in human4 One of the vaccine candidates from asexual blood stage is a 19 kDa C-
terminal region of merozoite surface protein 1 (MSP-1C). MSP-1C protein has been 
considered as a good candidate for malaria vaccine development due to their obvious 
accessibility by host's immune response. The purpose of this project is to construct a DNA 
vaccine expressing MSP-1 C of P. falciparum, In order to develop this vaccine; MSP-1 C 
fragment was amplified from plasmid pNMN016 by using polymerase chain reaction 
(PCR). The MSP-1C fragment was ligated into pVAX1, a plasmid vector that is designed 
for use in the development of DNA vaccines. Hopefully, the development of DNA vaccine 
against P. falciparum would decline the number of malaria cases worldwide. 
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ABSTRAK 
Malaria merupakan salah satu penyakit merbahaya yang disebabkan oleh parasit dan 
biasanya ditemui di kawasan tropika dan subtropika. Masalah ini menjadi semakin parah 
apabila meningkatnya kerintangan parasit Plasmodium falciparum terhadap drug anti-
malaria, kerintangan nyamuk Anopheles terhadap insektisid, penjagaan kebersihan yang 
terabai, masalah sosioekonomi dan penghijrahan penduduk berlaku secara mendadak. 
Oleh itu, vaksin yang lebih efektif dan universal harus dibangunkan. Pada hari ini, para 
saintis telah berusaha keras dalam membangunkan vaksin malaria yang mempunyai 
sasaran pada fasa eritrositik disebabkan oleh kitar hidup parasit dalam darah adalah lebih 
lama berbanding fasa pra-eritrositik dan pembinaan vaksin pada fasa ini secara langsung 
boleh mengurangkan kes morbiditi dan mortaliti penyakit malaria dalam manusia. Salah 
satu calon vaksin pada fasa eritrasitik adalah 19 kDa C-terminal region daripada protein 
permukaan merozoit 1 (MSP-1C). MSP-1C telah dikenalpasti sebagai calon vaksin yang 
berpatensi untuk penyakit malaria kerana protein ini terdedah secara langsung kepada 
sistem imun perumah. Tujuan projek ini dijalankan adalah untuk membangunkan vaksin 
DNA yang mengekspreskan MSP-1 C yang terdapat pada P. falciparum. Dalam 
membangunkan vaksin ini, fragmen MSP-1C diamplifikasi daripada plasmid pNMN016 
dengan menggunakan tindakbalas rantai polimerase (PCR). Fragmen MSP-1C 
kemudiannya diligasi ke dalam vektor pVAX1 iaitu plasmid vektor yang direkabentuk khas 
untuk pembangunan vaksin DNA. Diharapkan pembangunan vaksin DNA yang 





1.1 Malaria disease 
Malaria is still one of a major cause of disease and death in many regions of the world. 
More than 500 million individuals contact malaria annually and approximately 1 million 
die, most of them are infants, young children and pregnant women (World Health 
Organization, 2007). Malaria can be transmitted to people of all ages (WHO, 2007). The 
common first symptoms of malaria are fever, headache, chills and vomiting (Boon et al., 
2006; WHO, 2007). These symptoms would appear 10 to 15 days after a person is 
infected. If not treated promptly with effective medicines, malaria can cause severe 
illness that is usually fatal (WHO, 2007). 
Malaria is caused by the Plasmodium parasites, transmitted to vertebrates by the bite of 
a female Anopheles mosquito. The parasite's asexual blood forms (merozoites and 
schizonts) are those life cycle stages responsible for plasmodial morbidity and mortality 
in the vertebrate host (Phillips, 2001). There are four species of humans malaria 
parasites; Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax and 
Plasmodium ova/e. The majority of deaths from malaria are due toP. falciparum, the 
disease's most aggressive causative agent (WHO, 2007). 
Most of malaria cases and deaths are in sub-Saharan Africa. However, Asia, Latin 
America, the Middle East and parts of Europe are also affected {WHO, 2007). Following 
WHO-sponsored campaigns focusing on prevention and effective treatment, the 
incidence of malaria was greatly reduced between 1950 and 1960, but since1970 there 
l 
has been resurgence. According to Boon et. al (2006), this problem has been 
reemergence due to resistance P. falciparum to chloroquine, notably in Asia and Africa. 
Increasing in travel and neglect of chemoprophylaxis cause over 2000 malaria cases 
imported annually into Britain. Most of the cases are due to P. falciparum, usually from 
Africa, and 1% of them died due to late diagnosis. Immigrants returning home after a 
long residence in United Kingdom are particularly at risk, they have lost their partial 
immunity and do not realize that they should be taking malaria prophylaxis. A few 
people living near airports in Europe have acquired malaria from accidentally imported 
mosquitoes (Boon et al., 2006). The endemic area of malaria and P. falciparum 
parasites in human blood are depicted in figure 1.1 and 1.2, respectively. 
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Figure 1.1: Areas of the world where malaria is endemic (WHO, 2005) 
P. falciparum 
Figure 1.2: P. falciparum in hum at'! biood (Britton, 2001) 
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1.2 Malaria in Malaysia 
According to WHO (2005), malaria remains the most common vector-borne parasitic 
disease in Malaysia despite a decline in the annual number of cases (Table 1.1). P. 
falciparum is the most predominant species in Malaysia followed by P. vivax and P. 
ma/ariae (Singh et al., 2001). 
The malaria prevalence data for Malaysia is based on microscopy-confirmed cases, 
and the majority of malaria cases was detected when individuals who were ill sought 
treatment at hospitals or rural health clinics (Ministry of Health Malaysia, 1999; Singh et 
al., 2001 ). However, the prevalence of Plasmodium species in Malaysia is probably 
underestimated because self-medicated individuals and sub-clinical or microscopy-
negative infections were not included in malaria case reports (Singh et al., 2001). 
Table 1.2 shows the reported malaria cases by age and gender in Malaysia from year 
2000 until year 2003 (WHO, 2005). Among gender, malaria cases for male are higher 
than female; while among age, more than 5 years old individuals are higher contact in 
malaria cases compared to less than 5 years old children. 
Malaysia can be divided into 3 geographically distind regions with respect to malaria 
transmission: Peninsular Malaysia, Sabah and Sarawak. According to the table 1.3, 
Sarawak shows the majority reported cases (41%), followed by Peninsular Malaysia 
(31°A»), and Sabah (28%). Among Peninsular Malaysia region, Pahang has been shown 
the highest malaria cases compared to the other regions (WHO, 2005). 
4 















Table 1.1: Reported malaria cases in Malaysia (WHO, 2005) 
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Grou~ Subarou~ 2000 . 2001 2002 2003 % 
Total 12 705 12 780 11 019 6 338 100 
Gender Male 8633 8 817 7 527 4483 71 
Female 4072 3963 3492 1 855 29 
Age <5 years 1 795 1 723 1486 607 10 
5> years 10 910 11 057 9533 5 731 90 fJ 
'"""""""'" -.... - ~ 
Table 1.2: Reported malaria cases by age and gender in Malaysia (WHO, 2005) 
15 of 15 areas 2000 2001 2002 2003 % 
Sarawak 3 011 3 145 2496 2 615 41 
Sabah 5 776 6050 5096 1 770 28 
Pahang 1 301 1 544 1 563 850 13 
Johor 710 671 579 284 4 
Perak 852 470 280 276 4 J 
Selangor 271 172 159 119 2 
Pulau Pinang 209 197 76 106 2 
Kelantan 386 184 333 99 2 
Kedah 12 26 82 92 1 ~ 
Terengganu 94 76 140 47 1 
Negeri Sembilan 37 205 180 45 1 
W.P.Kuala Lumpur 27 20 15 20 <1 
W.P.Labuan 7 <1 
Mel aka 18 15 16 7 <1 
Pert is 1 5 4 1 <1 
-
Table 1.3: Reported malaria cases by selected sub national area in Malaysia 
(WHO, 2005) 
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1.3 Pathogenesis of P. falciparum 
1.3.1 Life cycle of P. falciparum 
The life cycle of P. falciparum is complex. It involves a mosquito vector in which sexual 
stage takes place and human hosts in which asexual stage takes place (figure 1.3). The 
female Anopheline mosquito becomes infected when it feeds on human blood 
containing gametocytes (Boon et al., 2006). In the mosquito, the malarial parasite 
undergoes sexual reproduction to produce the infectious stage parasite, called 
sporozoite (Greenbaum, 2008). Development of the parasites in the mosquito normally 
takes about 7-20 days (Boon et al., 2006). When the mosquito takes a bloodmeal, it will 
inject sporozoites into the human host (Greenbaum, 2008). Immediately after these 
sporozoites enter the circulatory system, they will invade the liver cells within 30 to 60 
minutes (Boon et al., 2006). After invading the liver cell for some days, the parasite 
undergoes asexual reproduction, followed by differentiation into thousands of merozoite 
stage parasites, which flow into the blood stream to begin the erythrocytic cycle 
(Greenbaum, 2008). 
Merozoites released from infected liver cells into the blood stream and invade red blood 
cells (RBCs). Again, asexual reproduction occurs with as many as 36 merozoites being 
produced in one RBC. In the erythrocyte, the merozoite goes through ring, trophozoite 
and schizont stages. The stage of merozoite within erythrocyte is illustrated in figure 
1.4. The merozoites spill into the blood once again when the schizont ruptures. This 
RBC cycle is chronic and cycles every 48 hours. During this stage, the malaria 
associate morbidity and mortality occur. At some frequency during erythrocytic cycle 
sexual forms, gametocytes are produced. The gametocytes are then taken up by 
another mosquito during a blood meal. The sexual between a macro-gametocyte and 
7 
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Figure 1.4: 6ife cycle of P. falciparum parasites in erythrocyte (adapted from 
Greenbaum, 2008) 
Figure 1.5: Scanning electron micrograph of P. falciparum oocysts lining the Anopheles 
mosquito (adapted from 6oon et al.l 2006) 
9 
- - --- -- - --------- -- - -------- - - - - - ---
micro-gametocyte would be ingests by mosquito from a malaria-infected individual. The 
gametocytes combine and differentiate into sporozoites, which are eventually secreted 
into the blood stream of another human when the mosquito takes its next blood meal 
(Greenbaum, 2008). The figure 1.5 in the page 9 shows the scanning electron 
micrograph of P. falciparum oocysts lining the Anopheles mosquito. 
1.3.2 Pathology of malaria 
According to Boon et. al (2006), the pathology in malaria is due to haemolysis of 
infected RBC and adherence of infected RBC to capillaries. In P. fa/ciparum malaria 
disease, RBC containing schizonts adhere to capillary endothelium in brain, kidney, 
liver, lungs, and gut. The blood vessels become congested and the organs anoxic. 
Rupture of schizonts liberates toxic and antigenic substances that may cause further 
damage. The onset of infection is often insidious, with malaise, headache, cough, 
diarrhea and vomiting. Jaundice is also common in malaria cases due haemolysis and 
hepatic dysfunction. A patient with P. falciparum, apparently not seriously ill, may 
develop dangerous complication such as coma, hyperpyrexia, convulsion, 
hypoglycemia and acute renal failure. 
10 
1.4 Management of malaria 
1.4.1 Diagnosis 
The most common method used to diagnose malaria is via Giemsa stain of thick and 
thin blood film. The thick blood film is essential to check low level of parasitaemias 
while the thin blood film is essential to identify the species of parasite and essential to 
quantify the parasite load by counting the percentage of infected RBC (Boon et al., 
2006). Nowadays, immunochromatographic dipstick test are marketed and provide a 
useful non-microscopic diagnosis (Boon et al., 2006). According to K. Erdman and C. 
Kain (2008), nucleic acid based tests such as Polymerase Chain Reaction (PCR), 
Loop-mediated isothermal amplification (LAMP), Microarrays and Quantitative nucleic 
acid sequence-based amplification (QT -NASBA) are also introduced to provide more 
efficient result in diagnosis malaria disease. Nucleic acid based technique is very 
specific and sensitive tools but not suitable to apply as universal diagnosis tools 
because they are very expensive and require the expert to do the diagnosis. 
1.4.2 Treatment 
According to Centers for Disease Control and Prevention (2007), treatment against 
malaria should be guided by three main factors; 
1. The infecting Plasmodium species 
2. The clinical status of the patient 
3. The drug susceptibility of the infecting parasites 
For P. falciparum infections acquired in areas without chloroquine-resistant strains, 
patients should be treated with oral chloroquine. For P. falciparum infections acquired in 
areas with chloroquine-resistant strains, three treatment options are available. The first 
11 
two treatment options are quinine sulfate plus doxycycline, tetracycline, or clindamycin; 
or atovaquone-proguanil (Malarone). The third option, mefloquine, is associated with a 
higher rate of severe neuropsychiatric reactions when used at treatment doses. The 
third option treatment is recommended only when the quinine sulfate combination or 
atovaquone-proguanil options cannot be used. For pediatric patients, the treatment 
options are the same as for adults except the drug dose is adjusted by patient weight. 
The pediatric dose should never be exceeding the recommended adult dose. 
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1.5 Rationale of vaccines development 
The global resurgence of malaria today are due to the rapid spread of drug resistant P. 
falciparum, development of resistance to insecticides by anopheles mosquitoes, 
movement of population for seeking jobs, deterioration of socioeconomic conditions and 
environmental change (Krogstad, 1996; Marsh, 1998; Boon et al., 2006). Among 
reliable strategies to combat these prevailing problems involve the development of new 
drugs (WHO, 2007), restructuring G>f social economic condition (Singh et al., 2001), as 
well as the development of suitable candidate for vaccine. 
Although several vaccine candidate antigens of P. falciparum have been identified and 
characterized, the development of a universal malaria vaccine against P. falciparum is 
still a difficult challenge due to the antigenic variation of different geographic isolates of 
the parasite (Akram et al., 2007), and the difficulty in diagnosing clinical malaria 
(O'Meara et al., 2007). Thus, the urgent need for the development of an effective 
vaccine and other malaria control strategies would eradicate the prevalence of malaria 
disease to a more manageable level. 
There are several vaccines that have been developed against malaria disease, such 
as, irradiated sporozoites vaccines, SPff subunit vaccines, RTS,S recombinant 
vaccines, [NANP]19-5.1 recombinant vaccines and etceteras (Rapeah, 2003). The 
failures of these vaccines to curb the disease are due to antigenic variation in different 
geographic isolates of the parasite, impractical method to produce, expensive, short 
period immunity and its instability (Rapeah, 2003). Therefore, safer, easy to produce, 
relatively more stable, lower production cost as well as having a long term persistence 
of immunogens vaccines need to be developed. 
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